← Back to Search

Amino Acid Derivative

L-Carnosine for Schizophrenia (CACTIS Trial)

Phase 2 & 3
Waitlist Available
Led By Avi Reichenberg, PhD
Research Sponsored by Abraham Reichenberg
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Treatment with stable doses of antipsychotic medications for at least 4 weeks prior to the screening visit.
Age 18-60, males and females.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks and 10 weeks
Awards & highlights

CACTIS Trial Summary

This study is evaluating whether a drug may help improve cognition for individuals with schizophrenia.

CACTIS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

CACTIS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks and 10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognitive Training Score
Secondary outcome measures
Change in Performance Advantage
Matrix Consensus Cognitive Battery (MCCB)
The Learning Rate

CACTIS Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: L-CarnosineExperimental Treatment2 Interventions
oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
Group II: PlaceboPlacebo Group2 Interventions
matching placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cognitive Training
2008
Completed Phase 3
~4100
L-Carnosine
2015
Completed Phase 3
~60

Find a Location

Who is running the clinical trial?

Abraham ReichenbergLead Sponsor
Stanley Medical Research InstituteOTHER
140 Previous Clinical Trials
10,336 Total Patients Enrolled
83 Trials studying Schizophrenia
6,286 Patients Enrolled for Schizophrenia
Avi Reichenberg, PhDPrincipal InvestigatorIcahn School of Medicine at Mount Sinai

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025